Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.005 USD | +5.53% | +5.24% | -32.78% |
Mar. 25 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
Mar. 25 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 1,630 | 724.8 | 306.1 | 459 | 340 | 359.9 | - | - |
Enterprise Value (EV) 1 | 1,561 | 775.8 | 612.5 | 837.8 | 257.8 | 359.9 | 359.9 | 359.9 |
P/E ratio | -16.6 x | -4.97 x | -0.54 x | -1.77 x | -1.47 x | -4.71 x | 10.2 x | 1.71 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 11 x | 3.19 x | 3.9 x | 6.08 x | 2.92 x | 1.36 x | 0.89 x | 0.55 x |
EV / Revenue | 11 x | 3.19 x | 3.9 x | 6.08 x | 2.92 x | 1.36 x | 0.89 x | 0.55 x |
EV / EBITDA | -17.6 x | -6 x | -1.35 x | -2.56 x | -2.19 x | -3.8 x | 0.99 x | 1.04 x |
EV / FCF | -22.9 x | -8.42 x | -1.16 x | -2.63 x | -2.51 x | 2.9 x | 2.08 x | - |
FCF Yield | -4.38% | -11.9% | -86.2% | -38.1% | -39.8% | 34.5% | 48.1% | - |
Price to Book | 82.1 x | -7.01 x | -1.6 x | -1.28 x | -0.68 x | -0.9 x | -1.04 x | -1.19 x |
Nbr of stocks (in thousands) | 27,327 | 27,877 | 61,220 | 73,684 | 113,718 | 189,401 | - | - |
Reference price 2 | 59.63 | 26.00 | 5.000 | 6.230 | 2.990 | 1.900 | 1.900 | 1.900 |
Announcement Date | 2/27/20 | 2/23/21 | 2/22/22 | 2/21/23 | 2/27/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 148.4 | 227.5 | 78.45 | 75.48 | 116.3 | 265.2 | 405.6 | 659.2 |
EBITDA 1 | -92.78 | -120.8 | -226.1 | -179 | -155.4 | -94.7 | 363.4 | 345.6 |
EBIT 1 | -93.1 | -121.4 | -226.7 | -179.5 | -155.6 | -16.44 | 105.8 | 285.1 |
Operating Margin | -62.75% | -53.35% | -289.02% | -237.83% | -133.72% | -6.2% | 26.08% | 43.25% |
Earnings before Tax (EBT) 1 | -97.16 | -143.6 | -269.1 | -233.7 | -209.2 | -67.13 | 108.9 | 374.2 |
Net income 1 | -97.16 | -143.6 | -269.1 | -233.7 | -209.2 | -69.55 | 60.42 | 255.8 |
Net margin | -65.49% | -63.09% | -343.04% | -309.58% | -179.87% | -26.23% | 14.9% | 38.8% |
EPS 2 | -3.590 | -5.230 | -9.310 | -3.520 | -2.030 | -0.4038 | 0.1855 | 1.113 |
Free Cash Flow 1 | -71.29 | -86.05 | -263.8 | -174.8 | -135.5 | 124 | 173 | - |
FCF margin | -48.05% | -37.81% | -336.29% | -231.64% | -116.46% | 46.76% | 42.65% | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | 47.61% | - |
FCF Conversion (Net income) | - | - | - | - | - | - | 286.31% | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 2/27/20 | 2/23/21 | 2/22/22 | 2/21/23 | 2/27/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 14.41 | 15.4 | 18.84 | 18.84 | 18.98 | 18.82 | 24.33 | 25.79 | 50.12 | 33.97 | 32.25 | 84.51 | 42.53 | 68.46 | 69.8 | 79 |
EBITDA 1 | -55.59 | -55.48 | -42.84 | -52.23 | -41.52 | -42.42 | -48.52 | -37.01 | - | -27.51 | -42.36 | -39.5 | -34.3 | -16.3 | -4.6 | - |
EBIT 1 | -55.74 | -55.63 | -42.99 | -52.38 | -41.62 | -42.51 | -48.6 | -37.06 | - | -27.53 | -42.37 | 31.67 | -23.97 | -5.092 | -12.63 | 12.4 |
Operating Margin | -386.88% | -361.2% | -228.23% | -277.99% | -219.3% | -225.92% | -199.78% | -143.71% | - | -81.05% | -131.37% | 37.48% | -56.36% | -7.44% | -18.09% | 15.7% |
Earnings before Tax (EBT) 1 | -69.39 | -65.12 | -56.73 | -66.32 | -55.12 | -55.49 | -61.72 | -49.94 | - | -41.25 | -56.34 | 5.2 | -39.22 | -16.22 | -18.1 | -2.5 |
Net income 1 | -69.39 | -65.12 | -56.73 | -66.32 | -55.12 | -55.49 | -61.72 | -49.94 | - | -41.25 | -56.34 | 7.466 | -38.24 | -19.41 | -23.91 | -2.5 |
Net margin | -481.55% | -422.82% | -301.18% | -352.02% | -290.4% | -294.86% | -253.68% | -193.65% | - | -121.43% | -174.71% | 8.83% | -89.92% | -28.36% | -34.25% | -3.16% |
EPS 2 | -2.620 | -1.770 | -0.9300 | -1.050 | -0.8100 | -0.7600 | -0.7900 | -0.4600 | - | -0.3700 | -0.5000 | 0.0494 | -0.2061 | -0.1024 | -0.1332 | -0.0100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/2/21 | 2/22/22 | 5/3/22 | 8/2/22 | 11/1/22 | 2/21/23 | 5/9/23 | 8/1/23 | 8/1/23 | 11/7/23 | 2/27/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | 51 | 306 | 379 | - | - | - | - |
Net Cash position | 68.2 | - | - | - | 82.2 | - | - | - |
Leverage (Debt/EBITDA) | - | -0.4221 x | -1.355 x | -2.116 x | - | - | - | - |
Free Cash Flow 1 | -71.3 | -86 | -264 | -175 | -135 | 124 | 173 | - |
ROE (net income / shareholders' equity) | -196% | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | -54.3% | -50.6% | -73.2% | -74.2% | -92.2% | -11.6% | 4.75% | 4.22% |
Assets 1 | 178.9 | 283.9 | 367.4 | 314.8 | 226.9 | 598.1 | 1,272 | 6,055 |
Book Value Per Share 2 | 0.7300 | -3.710 | -3.130 | -4.880 | -4.410 | -2.110 | -1.820 | -1.600 |
Cash Flow per Share 2 | - | -3.100 | -9.130 | -2.630 | -1.310 | 0.3400 | -0.2200 | - |
Capex | 0.95 | 0.87 | - | - | - | - | - | - |
Capex / Sales | 0.64% | 0.38% | - | - | - | - | - | - |
Announcement Date | 2/27/20 | 2/23/21 | 2/22/22 | 2/21/23 | 2/27/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.94% | 360M | |
+25.98% | 661B | |
+26.74% | 566B | |
-6.76% | 352B | |
+19.19% | 332B | |
+3.18% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.42% | 145B |
- Stock Market
- Equities
- ESPR Stock
- Financials Esperion Therapeutics, Inc.